ArticleThe lancet. HIV2022
Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19.
Article in The lancet. HIV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06683937 (Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024), which is not on this map. Cited by 117 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Direct Antiviral Treatments Against SARS-CoV-2 in Immunocompromised Patients With Covid-19. A G2i Study, National Multicenter Observational and Retrospective From June 2023 to April 2024
Who cites it
117 citing papers in PubMed, 2 syntheses or guidelines pooled it, 190 citations in OpenAlex.
- Exit Meta-Analysis on the Effect of HIV on COVID-19 Mortality, Hospitalization, and ICU Admission.Medical sciences (Basel, Switzerland) · 2025Pooled it
- A systematic review and meta-analysis of the global prevalence and determinants of COVID-19 vaccine acceptance and uptake in people living with HIV.Nature human behaviour · 2024Pooled it
- Safety and Immunogenicity of BNT162b2 in Antiretroviral Therapy-Treated People With HIV.Open forum infectious diseases · 2026Trial
- Effects of Pitavastatin on COVID-19 Incidence and Seriousness Among a Global Cohort of People With HIV.Open forum infectious diseases · 2024Trial
- Observational
- HIV-1 viral load and reservoir size remain stable following SARS-CoV-2 mRNA vaccination in people with HIV.HIV medicine · 2026Article
- Distinct Patterns of Clinical Features and Cardiac Biomarker Elevation in Community-Acquired Pneumonia and COVID-19 Pneumonia.Pathogens (Basel, Switzerland) · 2026Article
- Brief communication: COVID-19 in patients with HIV-a prospective, single-centre cohort study in Slovakia.AIDS research and therapy · 2026Article
- Antiretroviral therapy interferes with pseudovirus neutralization assays while Gag-specific T-cells influence mRNA vaccine outcomes in HIV patients.Scientific reports · 2026Article
- Humoral Immunogenicity of SARS-CoV-2 mRNA Primary Vaccination Among People with HIV.Microorganisms · 2026Article
- High risk of COVID-19 mortality in people living with advanced HIV disease in South Africa: A retrospective cohort study.Medicine · 2026Article
- Article
- Leveraging remnant viral load samples for SARS-CoV-2 antibody seroprevalence trends among PLHIV in Kenya, February 2021-October 2022: a cross-sectional surveillance survey.BMJ public health · 2026Article
- Humoral and cellular responses to SARS-CoV-2 variants after ancestral COVID-19 vaccines in people with HIV and lung transplant recipients.Clinical & translational immunology · 2026Article
- Understanding the Burden of Coinfection: COVID-19 in Hospitalized Patients with Diagnosed and Undiagnosed Advanced HIV.Current HIV research · 2026Article
- Effect of Antiretroviral Therapy, Immune Dysregulation, and COVID-19 Vaccination on SARS-CoV-2 Outcomes in PLWHA in Kenya.AIDS research and treatment · 2026Article
- Continuous antiretroviral therapy induces progressive senescence-like reprogramming of alveolar macrophages.Frontiers in immunology · 2026Article
- Syndemic perspective of how people living with HIV faced the COVID-19 crisis in North Africa.Scientific reports · 2025Article
- Risk factors for long COVID among participants of a population-based study in urban and rural Kenya, 2021.BMC public health · 2025Article
- Plasma proteomic signatures in HIV-infected individuals post-SARS-CoV-2 infection.BMC infectious diseases · 2025Article
57 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
11 authors at 6 institutions in 6 countries.
Funding
Abstract
backgroundWHO has established a Global Clinical Platform for the clinical characterisation of COVID-19 among hospitalised individuals. We assessed whether people living with HIV hospitalised with COVID-19 had increased odds of severe presentation and of in-hospital mortality compared with individuals who were HIV-negative and associated risk factors.
methodsBetween Jan 1, 2020, and July 1, 2021, anonymised individual-level data from 338 566 patients in 38 countries were reported to WHO. Using the Platform pooled dataset, we performed descriptive statistics and regression analyses to compare outcomes in the two populations and identify risk factors.
findingsOf 197 479 patients reporting HIV status, 16 955 (8·6%) were people living with HIV. 16 283 (96.0%) of the 16 955 people living with HIV were from Africa; 10 603 (62·9%) were female and 6271 (37·1%) were male; the mean age was 45·5 years (SD 13·7); 6339 (38·3%) were admitted to hospital with severe illness; and 3913 (24·3%) died in hospital. Of the 10 166 people living with HIV with known antiretroviral therapy (ART) status, 9302 (91·5%) were on ART. Compared with individuals without HIV, people living with HIV had 15% increased odds of severe presentation with COVID-19 (aOR 1·15, 95% CI 1·10-1·20) and were 38% more likely to die in hospital (aHR 1·38, 1·34-1·41). Among people living with HIV, male sex, age 45-75 years, and having chronic cardiac disease or hypertension increased the odds of severe COVID-19; male sex, age older than 18 years, having diabetes, hypertension, malignancy, tuberculosis, or chronic kidney disease increased the risk of in-hospital mortality. The use of ART or viral load suppression were associated with a reduced risk of poor outcomes; however, HIV infection remained a risk factor for severity and mortality regardless of ART and viral load suppression status.
interpretationIn this sample of hospitalised people contributing data to the WHO Global Clinical Platform for COVID-19, HIV was an independent risk factor for both severe COVID-19 at admission and in-hospital mortality. These findings have informed WHO immunisation policy that prioritises vaccination for people living with HIV. As the results mostly reflect the data contribution from Africa, this analysis will be updated as more data from other regions become available.
fundingNone. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.